Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

More on Johnson & Johnson (JNJ): Pharmaceutical sales in the U.S. rose 14.6% Y/Y to $3.288B. On...

  • Tuesday, October 16, 2012, 8:01 AM ET
    More on Johnson & Johnson (JNJ): Pharmaceutical sales in the U.S. rose 14.6% Y/Y to $3.288B. On a regional basis, gains in the Western Hemisphere and Asia-Pacific Africa helped to offset a 3.4% decline of revenue in Europe. Sees full-year 2012 EPS of $5.05-$5.10, lower than prior guidance of $5.00-$5.07 and the consensus mark of analysts calling for $5.06. Shares +1.2% premarket. (PR)
Track new comments on this story

This news story has 4 comments:

  •  
    I think the guidance would be higher
    16 Oct 2012, 08:02 AM Reply Like
  •  
    Nice increases considering we cannot get anything from Congress or President on direction. The fiscal cliff is coming, I'm surprised things are this good. VOTE
    16 Oct 2012, 08:07 AM Reply Like
  •  
    Agreed. JNJ continues to deliver, even when analysts are rating them a sell. What a joke.
    16 Oct 2012, 08:12 AM Reply Like
  •  
    Fwiw, M* still considers JNJ as "undervalued", pointing to a strong pipeline of new drugs more than offsetting weak performance in their consumer segment.
    16 Oct 2012, 08:05 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)
Latest Consumer Articles
More Latest Articles »